Stocks · News reference
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
CDT Equity Inc. has issued a statement welcoming new U.S. regulatory developments that facilitate broader access to compounded peptides.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CDT Equity Enters Evaluation Agreement with Manoira Corporation
CDT Equity Inc. has signed an evaluation agreement with Manoira Corporation to assess the potential of its clinical-stage assets, AZD1656 and AZD5904, for use in animal health products.
Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Dow Gains Over 100 Points; US Inflation Rate Rises In September
U.S. stocks mixed: Dow up, Nasdaq and S&P down as September inflation hits 3.7%, above forecasts. Oil rises; gold and silver fall.
CDT Equity shares are trading lower. The company highlighted announcement from Sarborg regarding intellectual property covering solid forms of a major respiratory medicine.
CDT Equity Announces Patent Filing From Sarborg Limited For Its Intellectual Property Covering Novel Solid Forms Of Respiratory Medicine
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory